A pronounced inflammatory activity characterizes the early fracture healing phase in immunologically restricted patients

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Hoff, Paula ^a,b,c,d   Gaber, Timo ^a,b,e   Strehl, Cindy ^a,b   Jakstadt, Manuela ^a,b   Hoff, Holger ^b   Schmidt Bleek, Katharina ^a   Lang, Annemarie ^a,b,f   Röhner, Eric ^c   Huscher, Dörte ^a,b   Matziolis, Georg ^c   Burmester, Gerd Rüdiger ^a,b   Schmidmaier, Gerhard ^g   Perka, Carsten ^a,e   Duda, Georg N ^a,e   Buttgereit, Frank ^a,b,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c Jena University Hospital   (Germany)

^d Endokrinologikum Berlin   (Germany)

^e Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^f Berlin Brandenburg School for Regenerative Therapies (BSRT)   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bone healing; Chemokines; Cytokines; Fracture healing; Fracture hematoma; Immune cells; Immunologically restricted patients; Inflammation

Indexed keywords

EOTAXIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; RANTES; TUMOR NECROSIS FACTOR; ANGIOGENIC FACTOR; AUTACOID; CYTOKINE;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FRACTURE; FRACTURE HEALING; HELPER CELL; HEMATOMA; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL PARAMETERS; IMMUNOLOGICAL RESTRICTION; INFLAMMATION; MACROPHAGE; MALE; MONOCYTE; NATURAL KILLER T CELL; VERY ELDERLY; ANGIOGENESIS; CASE CONTROL STUDY; HEMATOPOIETIC STEM CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PATHOLOGY; PHENOTYPE;

ANGIOGENESIS INDUCING AGENTS; BONE MARROW; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FRACTURE HEALING; FRACTURES, BONE; HEMATOMA; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE;

EID: 85014830973     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030583     Document Type: Article

References (45)

1. Chidrawar, S.M.; Khan, N.; Chan, Y.L.; Nayak, L.; Moss, P.A. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun. Ageing 2006, 3, 10. [CrossRef] [PubMed]
2. Ishikawa, M.; Nishioka, M.; Hanaki, N.; Miyauchi, T.; Kashiwagi, Y.; Kawasaki, Y.; Miki, H.; Kagawa, H.; Ioki, H.; Nakamura, Y. Postoperative host responses in elderly patients after gastrointestinal surgery. Hepatogastroenterology 2006, 53, 730–735. [PubMed]
3. Kang, S.C.; Matsutani, T.; Choudhry, M.A.; Schwacha, M.G.; Rue, L.W.; Bland, K.I.; Chaudry, I.H. Are the immune responses different in middle-aged and young mice following bone fracture, tissue trauma and hemorrhage? Cytokine 2004, 26, 223–230. [CrossRef] [PubMed]
4. Smith, R.M. Immunity, trauma and the elderly. Injury 2007, 38, 1401–1404. [CrossRef] [PubMed]
5. Woodland, D.L.; Blackman, M.A. Immunity and age: Living in the past? Trends Immunol. 2006, 27, 303–307. [CrossRef] [PubMed]
6. Hadjiargyrou, M.; O’Keefe, R.J. The convergence of fracture repair and stem cells: Interplay of genes, aging, environmental factors and disease. J. Bone Miner Res. 2014, 29, 2307–2322. [CrossRef] [PubMed]
7. Bogoch, E.R.; Moran, E.L. Bone abnormalities in the surgical treatment of patients with rheumatoid arthritis. Clin. Orthop. Relat. Res. 1999, 366, 8–21. [CrossRef]
8. Busti, A.J.; Hooper, J.S.; Amaya, C.J.; Kazi, S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 2005, 25, 1566–1591. [CrossRef] [PubMed]
9. Dominiak, B.; Oxberry, W.; Chen, P. Study on a nonhealing fracture from a patient with systemic lupus erythematosus and its pathogenetic mechanisms. Ultrastruct. Pathol. 2005, 29, 107–120. [CrossRef] [PubMed]
10. Park, J.E.; Barbul, A. Understanding the role of immune regulation in wound healing. Am. J. Surg. 2004, 187, 11S–16S. [CrossRef]
11. Kolar, P.; Schmidt-Bleek, K.; Schell, H.; Gaber, T.; Toben, D.; Schmidmaier, G.; Perka, C.; Buttgereit, F.; Duda, G.N. The early fracture hematoma and its potential role in fracture healing. Tissue. Eng. Part B Rev. 2010, 16, 427–434. [CrossRef] [PubMed]
12. Hoff, P.; Gaber, T.; Schmidt-Bleek, K.; Senturk, U.; Tran, C.L.; Blankenstein, K.; Lutkecosmann, S.; Bredahl, J.; Schuler, H.J.; Simon, P.; et al. Immunological characterization of the early human fracture hematoma. Immunol. Res. 2016, 64, 1195–1206. [CrossRef] [PubMed]
13. Kolar, P.; Gaber, T.; Perka, C.; Duda, G.N.; Buttgereit, F. Human early fracture hematoma is characterized by inflammation and hypoxia. Clin. Orthop. Relat. Res. 2011, 469, 3118–3126. [CrossRef] [PubMed]
14. Hoff, P.; Gaber, T.; Schmidt-Bleek, K.; Senturk, U.; Tran, C.L.; Blankenstein, K.; Lutkecosmann, S.; Bredahl, J.; Schuler, H.J.; Simon, P.; et al. Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas. Immunol. Res. 2011, 51, 116–122. [CrossRef] [PubMed]
15. Komori, T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 2010, 339, 189–195. [CrossRef] [PubMed]
16. Komori, T. Signaling networks in RUNX2-dependent bone development. J. Cell Biochem. 2011, 112, 750–755. [CrossRef] [PubMed]
17. Nakashima, K.; de Crombrugghe, B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet. 2003, 19, 458–466. [CrossRef]
18. Xing, Z.; Lu, C.; Hu, D.; Yu, Y.Y.; Wang, X.; Colnot, C.; Nakamura, M.; Wu, Y.; Miclau, T.; Marcucio, R.S. Multiple roles for CCR2 during fracture healing. Dis. Model. Mech. 2010, 3, 451–458. [CrossRef] [PubMed]
19. Minutti, C.M.; Knipper, J.A.; Allen, J.E.; Zaiss, D.M. Tissue-specific contribution of macrophages to wound healing. Semin. Cell Dev. Biol. 2016, 61, 3–11. [CrossRef] [PubMed]
20. Ogilvie, P.; Bardi, G.; Clark-Lewis, I.; Baggiolini, M.; Uguccioni, M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001, 97, 1920–1924. [CrossRef] [PubMed]
21. Lange, J.; Sapozhnikova, A.; Lu, C.; Hu, D.; Li, X.; Miclau, T.; Marcucio, R.S. Action of IL-1β during fracture healing. J. Orthop. Res. 2010, 28, 778–784. [PubMed]
22. Mumme, M.; Scotti, C.; Papadimitropoulos, A.; Todorov, A.; Hoffmann, W.; Bocelli-Tyndall, C.; Jakob, M.; Wendt, D.; Martin, I.; Barbero, A. Interleukin-1β modulates endochondral ossification by human adult bone marrow stromal cells. Eur. Cell. Mater. 2012, 24, 224–236. [CrossRef] [PubMed]
23. Hengartner, N.E.; Fiedler, J.; Ignatius, A.; Brenner, R.E. IL-1β inhibits human osteoblast migration. Mol. Med. 2013, 19, 36–42. [CrossRef] [PubMed]
24. Schett, G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity 2008, 41, 224–229. [CrossRef] [PubMed]
25. Holbrook, S.T.; Ohls, R.K.; Schibler, K.R.; Yang, Y.C.; Christensen, R.D. Effect of interleukin-9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood 1991, 77, 2129–2134. [PubMed]
26. Xu, J.; Wang, Y.; Li, J.; Zhang, X.; Geng, Y.; Huang, Y.; Dai, K.; Zhang, X. IL-12p40 impairs mesenchymal stem cell-mediated bone regeneration via CD4+ T cells. Cell Death Differ. 2016, 23, 1941–1951. [CrossRef] [PubMed]
27. Gibon, E.; Lu, L.; Goodman, S.B. Aging, inflammation, stem cells, and bone healing. Stem Cell Res. Ther. 2016, 7, 44. [CrossRef] [PubMed]
28. Michalski, M.N.; Koh, A.J.; Weidner, S.; Roca, H.; McCauley, L.K. Modulation of osteoblastic cell efferocytosis by bone marrow macrophages. J. Cell. Biochem. 2016, 117, 2697–2706. [CrossRef] [PubMed]
29. Kariminekoo, S.; Movassaghpour, A.; Rahimzadeh, A.; Talebi, M.; Shamsasenjan, K.; Akbarzadeh, A. Implications of mesenchymal stem cells in regenerative medicine. Artif. Cells Nanomed. Biotechnol. 2016, 44, 749–757. [CrossRef] [PubMed]
30. Zurawski, G.; de Vries, J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 1994, 15, 19–26. [CrossRef]
31. Wynn, T.A. IL-13 effector functions. Annu. Rev. Immunol. 2003, 21, 425–456. [CrossRef] [PubMed]
32. Yadav, A.; Saini, V.; Arora, S. MCP-1: Chemoattractant with a role beyond immunity: A review. Clin. Chim. Acta 2010, 411, 1570–1579. [CrossRef] [PubMed]
33. Maurer, M.; von Stebut, E. Macrophage inflammatory protein-1. Int. J. Biochem. Cell Biol. 2004, 36, 1882–1886. [CrossRef] [PubMed]
34. Luther, S.A.; Cyster, J.G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2001, 2, 102–107. [CrossRef] [PubMed]
35. Wynn, T.A.; Barron, L. Macrophages: Master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010, 30, 245–257. [CrossRef] [PubMed]
36. Kaplan, A.P. Chemokines, chemokine receptors and allergy. Int. Arch. Allergy Immunol. 2001, 124, 423–431. [CrossRef] [PubMed]
37. Fu, R.; Liu, H.; Zhao, S.; Wang, Y.; Li, L.; Gao, S.; Ruan, E.; Wang, G.; Wang, H.; Song, J.; et al. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int. 2014, 14, 132. [CrossRef] [PubMed]
38. Yano, S.; Mentaverri, R.; Kanuparthi, D.; Bandyopadhyay, S.; Rivera, A.; Brown, E.M.; Chattopadhyay, N. Functional expression of β-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology 2005, 146, 2324–2335. [CrossRef] [PubMed]
39. Gaber, T.; Strehl, C.; Sawitzki, B.; Hoff, P.; Buttgereit, F. Cellular energy metabolism in T-lymphocytes. Int. Rev. Immunol. 2015, 34, 34–49. [CrossRef] [PubMed]
40. Chim, S.M.; Tickner, J.; Chow, S.T.; Kuek, V.; Guo, B.; Zhang, G.; Rosen, V.; Erber, W.; Xu, J. Angiogenic factors in bone local environment. Cytokine Growth Factor Rev. 2013, 24, 297–310. [CrossRef] [PubMed]
41. Clarkin, C.E.; Gerstenfeld, L.C. VEGF and bone cell signalling: An essential vessel for communication? Cell Biochem. Funct. 2013, 31, 1–11. [CrossRef] [PubMed]
42. Follak, N.; Kloting, I.; Merk, H. Influence of diabetic metabolic state on fracture healing in spontaneously diabetic rats. Diabetes Metab. Res. Rev. 2005, 21, 288–296. [CrossRef] [PubMed]
43. Kidder, L.S.; Chen, X.; Schmidt, A.H.; Lew, W.D. Osteogenic protein-1 overcomes inhibition of fracture healing in the diabetic rat: A pilot study. Clin. Orthop. Relat. Res. 2009, 467, 3249–3256. [CrossRef] [PubMed]
44. Stromqvist, B. Hip fracture in rheumatoid arthritis. Acta Orthop. Scand. 1984, 55, 624–628. [CrossRef] [PubMed]
45. Tyndall, W.A.; Beam, H.A.; Zarro, C.; O’Connor, J.P.; Lin, S.S. Decreased platelet derived growth factor expression during fracture healing in diabetic animals. Clin. Orthop. Relat. Res. 2003, 408, 319–330. [CrossRef]